Ipsen re­ceives new palo­varotene PDU­FA date; Ac­er halts de­vel­op­ment of ex-Sanofi drug

The FDA will be giv­ing Ipsen an­oth­er shot at ap­proval for one of its can­di­dates.

Ipsen an­nounced that the FDA has set the PDU­FA date for Aug. 16, 2023, as more in­for­ma­tion on palo­varotene’s clin­i­cal tri­al will be in­clud­ed in the re­sub­mis­sion. This com­pris­es more analy­ses across the clin­i­cal tri­al pro­gram, in­clud­ing the first Phase III study that was car­ried out in pa­tients with fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va, or FOP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER